Communicators

are winners!

More News

12.09.2023
Recce Pharmaceuticals: Strongly Supported $8m Placement – Launches $3m Entitlement Offer to Shareholders
06.09.2023
RECCE® Trademark Registered – Vietnam
01.09.2023
Recce Pharmaceuticals Limited: Additional Positive Patient Cases – Special Access Scheme
21.08.2023
Recce Pharmaceuticals Ltd. - Phase I/II Clinical Trial for the Treatment of Burn Wound Infections – Stage 1 Data Analysis Complete
08.08.2023
RECCE: Positive Patients Update – Special Access Scheme
03.08.2023
Australian Patent Granted for RECCE® Anti-Infectives
28.07.2023
Recce Pharmaceuticals Ltd. - Bonus Canadian Scientific Research & Experimental Development Rebate Received
28.07.2023
Recce Pharmaceuticals Ltd. - Scientia Clinical Research Completes Cohort Dosing of Phase I/II UTI Rapid Infusion Clinical Trial
24.07.2023
Scientia Clinical Research Subjects Dosed in RECCE® 327 Rapid Infusion Phase I/II UTI Clinical Trial
20.07.2023
Clarification – 5-fold Increase to Concentration of RECCE® 327 in Urine and Plasma